Abstract
Introduction: it is recommended to achieve diagnostic test to the patients with cognitive complaints; however, the yield of these tests has not been evaluated.
Objective: to determine the estimated yield of the diagnostic tests in patient with cognitive complaints, in patiens with dementia and subjects with mild cognitive impairment.
Materials and methods: the efficiency of, electroencephalogram, complete blood count, VDRL, glucose, creatinine, aminotransferases, prothrombin time, lipid profile, sodium, calcium, serum vitamin B12 and folic acid and TSH; and it was evaluated if the tests changed the initial diagnosis. The estimated diagnostic yield was calculated for each test. Odds ratio was used in order to evaluate the association of the variables studied with vascular pathology or abnormal images.
Results: 97 out of 229 patients with dementia and 40 out of 97 with mild cognitive impairment were included. The estimated yield of the diagnostic test were 0% (electroencephalogram, creatinine, prothrombin time, HDL, triglycerides and serum folic acid) and 40,5% (Magnetic Resonance). There ware no differences in the estimated yield among patient with dementia and mild cognitive impairment. The glucose, total cholesterol, LDL, sex, medical history of diabetes mellitus, hypertension or hipercholesterolemia did not were associated to new vascular pathology or abnormal images.
Conclusions: the yield of diagnostic tests is similar in patient with mild cognitive impairment and dementia. It was not detected any predict variable of vascular pathology or abnormal images, in these patients.
References
MAYEUX R. Alzheimer'disease:epidemiology. In Duyckaerts C, Litvan I eds. Handbook of Clinical Neurology. Elsevier 2008:195-205.
FELDMAN H, LEVY AR, HSIUNG G-Y, ET AL. A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD):study methods and baseline results. Neuroepidemiology 2003;22:265-74.
SEMPERE AP, CALLEJO-DOMÍNGUEZ JM, GARCÍA-CLEMENTE C, RUIPÉREZ-BASTIDA MC, MOLA-CABALLERO DE RODA S, GARCÍA-BARRAGÁN N, ET AL. Rentabilidad del estudio diagnóstico de la demencia en una consulta extra-hospitalaria de Neurología. Rev Neurol 2004;39:807-10.
SENTÍES-MADRID H, ESTAÑOL-VIDAL B. Demencias reversibles y demencias tratables. Rev Neurol 2006;43:101-12.
HEJL A, H0GH P, WALDEMAR G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002;73:390-394.
FRETER S, BERGMAN H, GOLD S, CHERT-KOW H, CLARFIELD AM. Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort. CMAJ 1998;159:657-62.
CLARFIELD AM. The Decreasing Prevalence of Reversible Dementias. An Updated Meta-analysis. Arch Intern Med 2003;163:2219-2229.
FELDMAN H, JACOVA C, ROBILLARD A, GARCIA A, CHOW T, BORRIE M, SCHIPPER HM, BLAIR M, KERTESZ A, CHERTKOW H. Diagnosis and treatment of dementia:2. Diagnosis. CMAJ 2008;178:825-36.
PETERSEN RC. Mild Cognitive Impairment. N Engl J Med 2011;364:2227-34.
SÁNCHEZ-RODRÍGUEZ JL, TORRELLAS-MORALES C. Revisión del constructo deterioro cognitivo leve:aspectos generales. Rev Neurol 2011;52:300-5.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., Text revised: DSM-IV-TR. Washington, D.C.: American Psychiatric Association; 2000.
PETERSEN RC. Mild Cognitive Impairment:Current Research and Clinical Implications. Semin Neurol 2007;27:22-31.
KIVIPELTO M, NGANDU T, FRATIGLIONI L, VIITANEN M, KAREHOLT I, WINBLAD B, HELKALA E-L, TUOMILEHTO J, SOININEN H, NISSINEN A. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease. Arch Neurol 2005;62:1556-1560.
MIELKE MM, ZANDI PP, SJÖGREN M, GUS-TAFSON D, ÖSTLING S, STEEN B, SKOOG I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64:1689-1695.
FRISONI G B. Structural imaging in the clinical diagnosis of Alzheimer1 s disease: problems and tools. J Neurol Neurosurg Psychiatry 2001;70:711-718.
PAPAGEORGIOU SG, CHRISTOU Y, KONTAXIS T, BONAKIS A, ANAGNOSTOULI M, POTAGAS C, KALFAKIS N. Dementia as presenting symptom of primary hyperparathyroidism:Favourable outcome after surgery. Clin Neurol Neurosurg 2008;110:1038-1040.
PATTERSON C, FEIGHTNER JW, GARCIA A, HSIUNG G-Y, MACKNIGHT C, SADOVNICK AD. Diagnosis and treatment of dementia:1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 2008;178:548-56.
KNOTTNERUS JA, VAN WEEL C, MURIS JWM. Evidence base of clinical diagnosis. Evaluation of diagnostic procedures. BMJ 2002;324:477-80.
EGGENBERGER E. Prion Disease. Neurol Clin 2007;25:833-842.
PALOP JJ, MUCKE L. Epilepsy and Cognitive Impairments in Alzheimer Disease. Arch Neurol 2009;66:435-440.
GOODACRE S, MCCABE C. An introduction to economic evaluation. Emerg Med J 2002;19:198-201.
PÉREZ-MARTÍNEZ DA, DE TOLEDO-HERAS M, SAIZ-DIAZ RA, CALANDRE L, BERMEJO E. Demencias reversibles en la consulta neurológica extrahospitalaria. Rev Neurol 1999;29:425-8.
CRAET S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia. Two Roads Converged. Arch Neurol 2009;66:300-305.
YAFFE K, WESTON AL, BLACKWELL T, KRUEGER KA. The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women. Arch Neurol 2009;66:324-328.
HELZNER EP, LUCHSINGER JA, SCARMEAS N, COSENTINO S, BRICKMAN AM, GLYMOUR MM, STERN Y. Contribution of Vascular Risk Factors to the Progression in Alzheimer Disease. Arch Neurol 2009;66:343-348.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.